Researchers discover how colon cancer mutates to escape the immune system

June 05, 2018

A UCLA-led study has found how colon cancer alters its genes during development in order to avoid detection by the immune system, creating a specific genetic imprint in the process.

This ability of cancer to change its genes -- a process called immunoediting -- had never been described in colon cancer before, and the new understanding could help researchers develop new immunotherapies that target those genetic changes.

"By identifying the evolution of changes needed to escape the immune system, researchers should be able to design treatments that empower the immune system to outsmart the cancer," said lead author Catherine Grasso, assistant professor of medicine at the David Geffen School of Medicine at UCLA. "We expect that in the future, we'll be testing new immunotherapies to prevent the development of colon cancer, while also using combinations of different agents to treat advanced cancers."

The research appeared in the June edition of the journal Cancer Discovery, published by the American Association for Cancer Research.

Investigators from the ">UCLA Jonsson Comprehensive Cancer Center, the Broad Institute, the Parker Institute for Cancer Immunotherapy and the Fred Hutchinson Cancer Institute used the genetic analyses of more than 1,200 colon cancers from the Cancer Genome Atlas, the Nurses' Health Study and the Health Professionals Follow-up Study. Because the cancers were sequenced at the DNA and RNA level, researchers were able to make highly detailed assessments of the changes made to evade the immune system.

Among their findings was that more mutated cancers, called MSI-high (for high microsatellite instability), have more alterations of genes that interact with the immune system. That's significant because the 15 percent of colon cancers in this category can currently be treated with a type of immunotherapy that acts on a specific receptor, known as PD-1, located on cells in the immune system. This receptor normally functions as a brake to the immune system.

Immunotherapy releases this brake, allowing the immune system to attack cancer cells when it recognizes their high frequency of mutations as abnormal. Knowing how cancer cells change could help scientists further refine immunotherapy treatments for such cancers.

The study also shed light on the 85 percent of colon cancers that are not MSI-high. These cancers have fewer mutations and are not usually attacked by the immune system; instead, they have alterations in Wnt signaling, a pathway important in cell development. The study documents the extent to which Wnt-activating mutations were associated with the lack of an immune response in the tumor.

"The genetic data show that colon cancer is being attacked by the immune system from the start, even before immunotherapies based on immune-checkpoint blockade have been given to patients," said Dr. Antoni Ribas, co-senior author of the study and a professor of medicine, surgery, and molecular and medical pharmacology at Geffen School of Medicine and director of the cancer center's Tumor Immunology Program.

Added Grasso: "There are many ways for the immune system to fail in recognizing and attacking a cancer cell due to mutations in the tumor cells and we found examples of them. Our data suggest that the number of mutations is not the sole predictor of infiltration of the cancer by immune cells, which has been reported frequently in the literature."

For example, Grasso and colleagues showed that as Wnt signaling increases, immune infiltration in colon cancer decreases. This suggested that inhibitors of WNT signaling could potentially stimulate immune infiltration, so that the tumors could respond to immunotherapy.
-end-
This study was funded by the Parker Institute for Cancer Immunotherapy, the National Institutes of Health, the Dana-Farber/Harvard Cancer Center, the Ressler Family Foundation, the Samuel Family Foundation, the Garcia-Corsini Family Fund, the Project P Fund, the Friends of the Dana-Farber Cancer Institute, the Bennett Family Foundation, the Entertainment Industry Foundation through the National Colorectal Cancer Research Alliance, the Stand Up to Cancer (SU2C) Colorectal Cancer Dream Team Translational Research Grant, the American Society of Clinical Oncology, the Tower Cancer Research Foundation, the Hope Foundation, the Tumor Immunology training grant, the Ontario Institute for Cancer Research, the R.A.C.E. Charities, and the Gensch family.

The UCLA Jonsson Comprehensive Cancer Center has more than 500 researchers and clinicians engaged in cancer research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the UCLA Jonsson Comprehensive Cancer Center is dedicated to promoting research and translating basic science into leading-edge clinical studies.

University of California - Los Angeles Health Sciences

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.